However, assuming that there is an association between FGFR1 amplification and prognostically unfavorable luminal B breast cancer, it may be hypothesized that FGFR inhibitors may improve the prognosis, particularly in patients who are suffering from highly proliferative, hormone receptor-positive breast cancer with FGFR1 amplification. Here, NR4A1 is linked to breast cancer.